Valuation: C4 Therapeutics, Inc.

Market Cap 400M 347M 323M 297M 561M 38.06B 567M 3.8B 1.49B 19.04B 1.5B 1.47B 63.07B P/E 2026 *
-3.87x
P/E 2027 * -3.6x
Enterprise Value 400M 347M 323M 297M 561M 38.06B 567M 3.8B 1.49B 19.04B 1.5B 1.47B 63.07B EV / Sales 2026 *
21.1x
EV / Sales 2027 * 20.9x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: C4 Therapeutics, Inc.

1 day+0.28%
1 week+2.84%
Current month+4.02%
1 month-15.81%
3 months+21.89%
6 months+111.70%
Current year+89.53%
1 week 3.36
Extreme 3.36
3.68
1 month 3.36
Extreme 3.36
4.42
Current year 1.69
Extreme 1.6901
5.17
1 year 1.69
Extreme 1.6901
5.17
3 years 1.06
Extreme 1.06
11.88
5 years 1.06
Extreme 1.06
51.21
10 years 1.06
Extreme 1.06
51.21
Manager TitleAgeSince
Chief Executive Officer 55 02/10/2020
Director of Finance/CFO 49 18/09/2023
Chief Tech/Sci/R&D Officer 56 28/10/2024
Director TitleAgeSince
Director/Board Member 74 01/12/2015
Director/Board Member 55 14/09/2020
Director/Board Member 55 16/03/2022
Date Insider Type Main position Quantity % Market Cap.
7/10/26 A Fiscal year

Chief Technology Officer

22,722 0.0206%
7/1/26 A Free

Director

3,341 0.0030%
7/1/26 A Free

Founder

2,650 0.0024%
Change 5-day change 1-year change 3-year change Capi.($)
+0.28%+2.84%+80.10%-1.90% 400M
+0.77%-1.05%+3.45%+15.10% 48.57B
+1.98%+9.05%+413.94%+532.17% 41.95B
+3.44%-4.65%+28.34%+8.81% 38.85B
+1.40%+0.10%+6.61%+61.93% 37.24B
+2.42%+5.72%+12.38%+44.79% 30.67B
-0.16%-3.11% - - 16.1B
+2.20%+0.48%+34.71%+127.15% 16.41B
+0.40%+1.98%+8.30%+19.14% 13.97B
+4.25%-8.23%-1.49%-35.46% 12.62B
Average +1.70%-0.42%+65.15%+85.75% 25.68B
Weighted average by Cap. +1.84%-0.11%+82.92%+120.43%

Financials

2026 *2027 *
Net sales 18.92M 16.39M 15.28M 14.05M 26.53M 1.8B 26.83M 180M 70.47M 900M 71.08M 69.51M 2.98B 19.14M 16.58M 15.45M 14.21M 26.83M 1.82B 27.13M 182M 71.27M 911M 71.89M 70.3M 3.02B
Net income -119M -103M -96.22M -88.5M -167M -11.33B -169M -1.13B -444M -5.67B -448M -438M -18.78B -151M -131M -122M -112M -211M -14.33B -214M -1.43B -561M -7.17B -566M -554M -23.75B
Net Debt - -
Logo C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
Employees
104
Date Price Change Volume
05/08/26 $3.620 +0.28% 2,556,298
04/08/26 $3.610 +3.14% 2,519,664
03/08/26 $3.500 +0.57% 2,244,210
31/07/26 $3.480 -4.92% 1,949,817
30/07/26 $3.660 +3.98% 3,149,151
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
3.620USD
Average target price
13.33USD
Spread / Average Target
+268.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CCCC Stock